| Uterine Leiomyoma |
1 |
1 |
| Fibroma |
0 |
0.91 |
| Uterus |
0 |
0.7 |
| Contraception |
0 |
0.55 |
| Pain Management |
0 |
0.21 |
| Dysfunctional Uterine Bleeding |
0 |
0.2 |
| Hemorrhage |
0 |
0.19 |
| Sterilization, Birth Control |
0 |
0.17 |
| Pelvic Pain |
0 |
0.15 |
| Pain |
0 |
0.65 |
| Pregnancy |
0 |
0.13 |
| Birth |
0 |
0.12 |
| Hysterectomy |
0 |
0.45 |
| Nurse Practitioners |
0 |
0.1 |
| Blood |
0 |
0.07 |
| Food and Drug Administration (FDA) |
0 |
0.05 |
| Jobs |
0 |
0.05 |
| Medical Life |
0 |
0.05 |
| Menopause |
0 |
0.05 |
| Tumor |
0 |
0.05 |
| Urinary Frequency |
0 |
0.05 |
| Healthcare and Medical Technology |
0 |
0.04 |
| Constipation |
0 |
0.03 |
| Patient Safety |
0 |
0.03 |
| Adverse Effects |
0 |
0.02 |
| Antifibrinolytics |
0 |
0.02 |
| Bladder |
0 |
0.02 |
| Clinical Research |
0 |
0.02 |
| Gonadotropin-Releasing Hormone (GnRH) Antagonist |
0 |
0.02 |
| Hemoglobin |
0 |
0.02 |
| Hysteroscopy |
0 |
0.02 |
| Interprofessional Continuing Education |
0 |
0.02 |
| Muscle |
0 |
0.02 |
| Progestin |
0 |
0.45 |
| Rectum |
0 |
0.02 |
| Reproductive Health |
0 |
0.02 |
| Tissue |
0 |
0.02 |